TechBio and Preliminary Diagnostics (part IV)
Hi everyone 👋 and welcome back to another edition of MetaphysicalCells 🛸 only for paid subscribers, this time is all about Preliminary Diagnosis (progress so far and specific companies in Europe):
⏩ TechBio and Preliminary Diagnostics (IV) (🔐).
TechBio and Preliminary Diagnosis: Progress So Far (part IV)
TechBio, a rapidly evolving field at the intersection of biotechnology and artificial intelligence (AI), is redefining the landscape of preliminary diagnostics. This interdisciplinary domain integrates advanced computational tools with biological data to enhance early disease detection, offering unprecedented precision and scalability in healthcare. By leveraging AI-driven algorithms and biotechnological innovations, TechBio addresses critical challenges in diagnostic accuracy, patient stratification, and personalized medicine. The significance of this field lies not only in its technological sophistication but also in its potential to transform healthcare delivery by enabling earlier interventions and improving patient outcomes.
For instance ✅ AIM-NASH, an AI-based tool recently qualified by the European Medicines Agency (EMA), demonstrates the potential of such technologies in diagnosing inflammatory liver diseases with high ⬆️ reliability (EMA qualifies first artificial intelligence tool to diagnose inflammatory liver disease (MASH) in biopsy samples). AIM-NASH leverages a ML model trained on over 100,000 annotations from 59 pathologists across nine clinical trials to diagnose inflammatory liver disease (MASH) in biopsy samples. By reducing variability in measuring disease activity, such as inflammation and fibrosis, AIM-NASH enhances the reliability and efficiency of clinical trials for new treatments.